Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study-Reference-Cited by-同舟云学术

Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study

Published:2023-01 Issue:1 Volume:83 Page:15-26
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Yu Evan Y.,Piulats Josep M.,Gravis Gwenaelle,Fong Peter C.C.,Todenhöfer Tilman,Laguerre Brigitte,Arranz Jose A.,Oudard Stephane,Massard Christophe,Heinzelbecker Julia,Nordquist Luke T.,Carles Joan,Kolinsky Michael P.,Augustin Marinela,Gurney Howard,Tafreshi Ali,Li Xin Tong,Qiu Ping,Poehlein Christian H.,Schloss Charles,de Bono Johann S.

Publisher

Elsevier BV

Subject

Urology

Reference40 articles.

1. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Prostate cancer. Version 4.2019. National Comprehensive Cancer Network; 2019.

2. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer;Fizazi;N Engl J Med,2017

3. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004

4. Sipuleucel-T immunotherapy for castration-resistant prostate cancer;Kantoff;N Engl J Med,2010

5. Corporation D. PROVENGE® (sipuleucel-T) suspension for intravenous infusion. Seattle, WA: Dendreon Corporation; 2014.

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The combination of immune checkpoint inhibitors and antibody-drug conjugates in the treatment of urogenital tumors: a review insights from phase 2 and 3 studies;Cell Death & Disease;2024-06-19

2. Beyond monotherapy: An era ushering in combinations of PARP inhibitors with immune checkpoint inhibitors for solid tumors;Biomedicine & Pharmacotherapy;2024-06

3. Pembrolizumab plus Abiraterone Acetate and Prednisone in Patients with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort D;European Urology Oncology;2024-06

4. Homologous Recombination Repair Gene Mutations in Prostate Cancer: Prevalence and Clinical Value;Advances in Therapy;2024-05-20

5. Metastatic castration-resistant prostate cancer and immune checkpoint inhibitors;Cancer Urology;2024-05-17